Equities

Maia Biotechnology Inc

Maia Biotechnology Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.72
  • Today's Change-0.09 / -2.36%
  • Shares traded296.54k
  • 1 Year change+61.74%
  • Beta--
Data delayed at least 15 minutes, as of May 24 2024 20:42 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

  • Revenue in USD (TTM)0.00
  • Net income in USD-23.72m
  • Incorporated2018
  • Employees13.00
  • Location
    Maia Biotechnology Inc444 West Lake StreetSuite 1700, Suite 1700CHICAGO 60606United StatesUSA
  • Phone+1 (312) 416-8592
  • Fax+1 (302) 655-5049
  • Websitehttps://maiabiotech.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Spero Therapeutics Inc110.98m23.40m79.76m46.003.510.82833.370.71870.42130.42132.081.790.792--3.962,412,565.0016.70-35.5221.73-41.75----21.09-124.40----0.00--93.9592.11149.14------
Serina Therapeutics Inc137.00k-20.96m79.93m4.00------583.44-14.07-14.070.0909-0.51210.0117--3.8634,250.00-179.27-194.46----67.8885.80-15,301.46-2,347.36---0.92741.70--317.65-36.69-41.49------
Assembly Biosciences Inc12.95m-51.36m81.32m65.00--2.48--6.28-11.22-11.222.765.950.1276--34.07199,200.00-50.60-39.69-66.58-44.03-----396.63-409.24----0.00-----13.5134.23---5.59--
NDT Pharmaceuticals Inc-100.00bn-100.00bn81.60m1.00--0.4556----------1.12-----------164.47---452.47-------6,891.36----0.00---100.00--87.56------
Maia Biotechnology Inc0.00-23.72m83.20m13.00---------1.57-1.570.00-0.28010.00----0.00-266.70---520.49-----------------------21.91------
Aclaris Therapeutics Inc31.12m-77.26m84.09m91.00--0.592--2.70-1.09-1.090.43921.990.1541--58.77341,967.00-38.27-47.29-42.29-53.8741.9944.00-248.28-549.18----0.00--5.0338.41-1.81---0.703--
Chimerix Inc41.00k-82.59m84.45m72.00--0.4851--2,059.74-0.9296-0.92960.00051.940.0002--0.1226569.44-36.50-30.45-39.59-34.09100.00---201,443.90-442.93----0.00---99.04-46.24-147.68---13.24--
SCYNEXIS Inc140.39m101.33m84.63m29.001.111.14--0.60282.012.012.891.961.49--136.304,840,862.00107.48-30.02175.37-36.3588.97--72.18-86.76--193.810.1433--2,652.72252.64206.74------
Cue Biopharma Inc7.02m-49.97m84.64m53.00--2.82--12.06-1.07-1.070.14950.61750.1035--8.80132,452.80-73.69-57.45-96.35-68.41-----711.84-810.87----0.1935--340.8836.884.30------
Anixa Biosciences Inc210.00k-10.74m84.85m4.00--3.43--404.06-0.3451-0.34510.00680.77490.0078--0.780752,500.00-40.49-59.69-41.26-62.61-----5,174.29-6,040.10----0.00-----28.3627.83------
Allovir Inc0.00-179.53m85.85m112.00--0.712-----1.65-1.650.001.050.00----0.00-92.50-52.85-100.98-57.72-------378,613.90----0.00-------12.87------
IO Biotech Inc0.00-88.50m86.96m68.00--0.7532-----1.86-1.860.001.750.00----0.00-66.79---72.66--------------0.00-------20.47------
Data as of May 24 2024. Currency figures normalised to Maia Biotechnology Inc's reporting currency: US Dollar USD

Institutional shareholders

2.82%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 2024281.68k1.37%
Centric Wealth Management LLCas of 31 Mar 202467.20k0.33%
Geode Capital Management LLCas of 31 Mar 202453.26k0.26%
Bridgeway Capital Management LLCas of 31 Mar 202445.70k0.22%
Jane Street Capital LLCas of 31 Mar 202425.07k0.12%
Citadel Securities LLCas of 31 Mar 202423.75k0.12%
Naviter Wealth LLCas of 31 Mar 202422.17k0.11%
SSgA Funds Management, Inc.as of 31 Mar 202421.30k0.10%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 202420.27k0.10%
Renaissance Technologies LLCas of 31 Mar 202419.00k0.09%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.